Share this video  

ASCO 2021 | Natural history of patients with advanced CCA with FGFR2 gene alterations or wild-type FGFR2

Cholangiocarcinoma (CCA) is a rare and molecularly heterogeneous disease typically associated with a poor prognosis; 10-16% of patients also present with FGFR2 fusions which allow for molecularly targeted therapies. Rachna T. Shroff, MD, University of Arizona Cancer Center, Tucson, AZ, discusses the findings of a retrospective, observational, natural history study using US-based genomic information to compare overall survival in patients with advanced CCA and FGFR2 fusions/rearrangements versus those with wild-type FGFR2. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.